180 related articles for article (PubMed ID: 7666600)
1. Angiotensin-converting enzyme inhibitor-induced anemia and treatment for erythrocytosis in renal transplant recipients.
Satoh S; Kaneko T; Seino K; Abe T; Omori S; Sugimura J; Fujioka T; Kubo T
Nihon Jinzo Gakkai Shi; 1995 Jun; 37(6):343-7. PubMed ID: 7666600
[TBL] [Abstract][Full Text] [Related]
2. Posttransplant erythrocytosis in renal transplant recipients at Jeddah Kidney Center, Kingdom of Saudi Arabia.
Basri N; Gendo MZ; Haider R; Abdullah KA; Hassan A; Shaheen FA
Exp Clin Transplant; 2007 Jun; 5(1):607-9. PubMed ID: 17617052
[TBL] [Abstract][Full Text] [Related]
3. Effect of the angiotensin-converting enzyme inhibitor enalapril on post-transplant erythrocytosis.
Marubayashi S; Yamamoto H; Shibata S; Fudaba Y; Miyata Y; Fukuma K; Okada K; Hinoi T; Ikeda M; Maeda T; Oshiro Y; Dohi K
Hiroshima J Med Sci; 1998 Sep; 47(3):121-4. PubMed ID: 9810784
[TBL] [Abstract][Full Text] [Related]
4. Long-term therapy for postrenal transplant erythrocytosis with ACE inhibitors: efficacy, safety and action mechanisms.
Montanaro D; Groupuzzo M; Boscutti G; Risaliti A; Bresadola F; Mioni G
Clin Nephrol; 2000 Apr; 53(4):suppl 47-51. PubMed ID: 10809436
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin-converting enzyme inhibition in the treatment of renal transplant erythrocytosis. Clinical experience and observation of mechanism.
Danovitch GM; Jamgotchian NJ; Eggena PH; Paul W; Barrett JD; Wilkinson A; Lee DB
Transplantation; 1995 Jul; 60(2):132-7. PubMed ID: 7624954
[TBL] [Abstract][Full Text] [Related]
6. Anemia and angiotensin-converting enzyme inhibition in renal transplant recipients.
Sizeland PC; Bailey RR; Lynn KL; Robson RA
J Cardiovasc Pharmacol; 1990; 16 Suppl 7():S117-9. PubMed ID: 1708009
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of contributing factors of post transplant erythrocytosis in renal transplant patients.
Ahmed S; Ahmed E; Naqvi R; Qureshi S
J Pak Med Assoc; 2012 Dec; 62(12):1326-9. PubMed ID: 23866484
[TBL] [Abstract][Full Text] [Related]
8. Influence of angiotensin-converting enzyme polymorphism gene, IGF-1, and other factors in the response rate of hematocrit to enalapril treatment in patients with posttransplant erythrocytosis.
Jimeno L; Rodado R; Barrios Y; Campos M; Llorente S; Nicolas F; Minguela A
Transplant Proc; 2005 Mar; 37(2):1012-3. PubMed ID: 15848608
[TBL] [Abstract][Full Text] [Related]
9. Association of post-renal transplant erythrocytosis and microalbuminuria: response to angiotensin-converting enzyme inhibition.
Mulhern JG; Lipkowitz GS; Braden GL; Madden RL; O'Shea MH; Harvilchuck H; Guarnera JM; Germain MJ
Am J Nephrol; 1995; 15(4):318-22. PubMed ID: 7573190
[TBL] [Abstract][Full Text] [Related]
10. Anemia in renal transplant recipients caused by concomitant therapy with azathioprine and angiotensin-converting enzyme inhibitors.
Gossmann J; Kachel HG; Schoeppe W; Scheuermann EH
Transplantation; 1993 Sep; 56(3):585-9. PubMed ID: 8212154
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers used for the treatment of hypertension appear to be safe in the early posttransplant period.
Formica RN; Friedman AL; Lorber MI; Bia MJ
Transplant Proc; 2004 Nov; 36(9):2675-8. PubMed ID: 15621121
[TBL] [Abstract][Full Text] [Related]
12. Ramipril in post-renal transplant erythrocytosis.
Esposito R; Giammarino A; De Blasio A; Martinelli V; Cirillo F; Scopacasa F; Federico S; Russo D
J Nephrol; 2007; 20(1):57-62. PubMed ID: 17347974
[TBL] [Abstract][Full Text] [Related]
13. Anemia due to losartan in hypertensive renal transplant recipients without posttransplant erythrocytosis.
Ersoy A; Kahvecioglu S; Ersoy C; Cift A; Dilek K
Transplant Proc; 2005 Jun; 37(5):2148-50. PubMed ID: 15964363
[TBL] [Abstract][Full Text] [Related]
14. Factors predisposing to post-renal transplant erythrocytosis. A prospective matched-pair control study.
Kessler M; Hestin D; Mayeux D; Mertes PM; Renoult E
Clin Nephrol; 1996 Feb; 45(2):83-9. PubMed ID: 8846535
[TBL] [Abstract][Full Text] [Related]
15. Role of ACE inhibitors in the treatment of erythrocytosis in patients with renal allograft.
Pisani F; Tisone G; Alciati E; Vennarecci G; Pieragostini E; Casciani CU
Transplant Proc; 1994 Oct; 26(5):2602-3. PubMed ID: 7940809
[No Abstract] [Full Text] [Related]
16. Long-term follow-up of ACE-inhibitor versus beta-blocker treatment and their effects on blood pressure and kidney function in renal transplant recipients.
Suwelack B; Kobelt V; Erfmann M; Hausberg M; Gerhardt U; Rahn KH; Hohage H
Transpl Int; 2003 May; 16(5):313-20. PubMed ID: 12759722
[TBL] [Abstract][Full Text] [Related]
17. [The effects of ACE inhibitor treatment and ACE gene polymorphism on erythropoiesis in chronic hemodialysis patients].
Hatano M; Yoshida T; Mimuro T; Kimata N; Tsuchiya K; Sanaka T; Nihei H
Nihon Jinzo Gakkai Shi; 2000 Oct; 42(8):632-9. PubMed ID: 11195399
[TBL] [Abstract][Full Text] [Related]
18. Influence of angiotensin I-converting enzyme polymorphism on development of post-transplant erythrocytosis in renal graft recipients.
Kedzierska K; Kabat-Koperska J; Safranow K; Domański M; Gołembiewska E; Bober J; Bohatyrewicz R; Ciechanowski K
Clin Transplant; 2008; 22(2):156-61. PubMed ID: 18339134
[TBL] [Abstract][Full Text] [Related]
19. Effects of losartan on the treatment of posttransplant erythrocytosis.
Navarro JF; García J; Macía M; Mora C; Chahin J; Gallego E; Méndez ML; del Castillo N
Clin Nephrol; 1998 Jun; 49(6):370-2. PubMed ID: 9696433
[TBL] [Abstract][Full Text] [Related]
20. New insights and treatment in posttransplant polycythemia (erythrocytosis) of renal recipients.
Sauron C; Berthoux P; Berthoux F; Alamartine E; Diab N; Broyet C; Hacini J
Transplant Proc; 1993 Feb; 25(1 Pt 2):1032-3. PubMed ID: 8382847
[No Abstract] [Full Text] [Related]
[Next] [New Search]
